Gritstone Oncology Inc (GRTS)

$0.65

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.63
    $0.67
    $0.65
    downward going graph

    2.77%

    Downside

    Day's Volatility :5.64%

    Upside

    2.96%

    downward going graph
  • $0.52
    $3.33
    $0.65
    downward going graph

    20.0%

    Downside

    52 Weeks Volatility :84.38%

    Upside

    80.48%

    downward going graph

Returns

PeriodGritstone Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
-19.25%
6.5%
0.0%
6 Months
-76.12%
7.1%
0.0%
1 Year
-66.32%
9.8%
0.0%
3 Years
-91.3%
14.2%
-20.2%

Highlights

Market Capitalization
75.2M
Book Value
$0.14
Earnings Per Share (EPS)
-1.24
Wall Street Target Price
3.83
Profit Margin
0.0%
Operating Margin TTM
-2284.79%
Return On Assets TTM
-52.07%
Return On Equity TTM
-187.15%
Revenue TTM
15.6M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
-28.7%
Gross Profit TTM
-91.5M
EBITDA
-137.1M
Diluted Eps TTM
-1.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.08
EPS Estimate Next Year
-0.99
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Gritstone Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 489.23%

Current $0.65
Target $3.83

Company Financials

FY18Y/Y Change
Revenue
1.2M
-
Net Income
-64.8M
↑ 56.55%
Net Profit Margin
-5.5K%
-
FY19Y/Y Change
Revenue
4.4M
↑ 267.73%
Net Income
-90.9M
↑ 40.37%
Net Profit Margin
-2.1K%
↑ 3373.96%
FY20Y/Y Change
Revenue
4.0M
↓ 7.51%
Net Income
-104.6M
↑ 15.05%
Net Profit Margin
-2.6K%
↓ 508.24%
FY21Y/Y Change
Revenue
46.7M
↑ 1057.22%
Net Income
-75.0M
↓ 28.35%
Net Profit Margin
-160.44%
↑ 2430.87%
FY22Y/Y Change
Revenue
9.3M
↓ 80.16%
Net Income
-113.1M
↑ 50.93%
Net Profit Margin
-1.2K%
↓ 1060.05%
FY23Y/Y Change
Revenue
1.3M
↓ 85.64%
Net Income
-138.5M
↑ 22.42%
Net Profit Margin
-10.4K%
↓ 9184.47%
Q4 FY22Q/Q Change
Revenue
1.3M
↑ 204.36%
Net Income
-30.7M
↑ 2.02%
Net Profit Margin
-2.3K%
↑ 4582.8%
Q1 FY23Q/Q Change
Revenue
542.0K
↓ 59.16%
Net Income
-34.0M
↑ 10.86%
Net Profit Margin
-6.3K%
↓ 3961.04%
Q2 FY23Q/Q Change
Revenue
400.0K
↓ 26.2%
Net Income
-35.3M
↑ 3.72%
Net Profit Margin
-8.8K%
↓ 2542.41%
Q3 FY23Q/Q Change
Revenue
1.6M
↑ 291.25%
Net Income
-38.4M
↑ 9.01%
Net Profit Margin
-2.5K%
↑ 6358.15%
Q4 FY23Q/Q Change
Revenue
29.0K
↓ 98.15%
Net Income
-30.8M
↓ 19.82%
Net Profit Margin
-106.3K%
↓ 103813.12%
Q1 FY24Q/Q Change
Revenue
49.0K
↑ 68.97%
Net Income
-40.4M
↑ 31.04%
Net Profit Margin
-82.4K%
↑ 23850.6%
FY18Y/Y Change
Total Assets
189.6M
↑ 61.6%
Total Liabilities
40.4M
↑ 102.0%
FY19Y/Y Change
Total Assets
184.4M
↓ 2.73%
Total Liabilities
50.0M
↑ 23.76%
FY20Y/Y Change
Total Assets
221.6M
↑ 20.16%
Total Liabilities
54.8M
↑ 9.56%
FY21Y/Y Change
Total Assets
278.1M
↑ 25.52%
Total Liabilities
62.0M
↑ 13.12%
FY22Y/Y Change
Total Assets
240.8M
↓ 13.43%
Total Liabilities
70.0M
↑ 12.82%
FY23Y/Y Change
Total Assets
177.8M
↓ 26.16%
Total Liabilities
125.9M
↑ 79.95%
Q4 FY22Q/Q Change
Total Assets
240.8M
↑ 17.3%
Total Liabilities
70.0M
↑ 2.31%
Q1 FY23Q/Q Change
Total Assets
210.0M
↓ 12.79%
Total Liabilities
69.1M
↓ 1.28%
Q2 FY23Q/Q Change
Total Assets
222.6M
↑ 6.04%
Total Liabilities
113.1M
↑ 63.67%
Q3 FY23Q/Q Change
Total Assets
187.2M
↓ 15.9%
Total Liabilities
113.2M
↑ 0.16%
Q4 FY23Q/Q Change
Total Assets
177.8M
↓ 5.05%
Total Liabilities
125.9M
↑ 11.2%
Q1 FY24Q/Q Change
Total Assets
137.2M
↓ 22.81%
Total Liabilities
123.2M
↓ 2.12%
FY18Y/Y Change
Operating Cash Flow
-38.2M
↑ 9.12%
Investing Cash Flow
-59.1M
↑ 77.74%
Financing Cash Flow
110.4M
↑ 15.27%
FY19Y/Y Change
Operating Cash Flow
-85.0M
↑ 122.76%
Investing Cash Flow
15.8M
↓ 126.8%
Financing Cash Flow
74.4M
↓ 32.64%
FY20Y/Y Change
Operating Cash Flow
-89.1M
↑ 4.81%
Investing Cash Flow
65.9M
↑ 316.32%
Financing Cash Flow
135.8M
↑ 82.54%
FY21Y/Y Change
Operating Cash Flow
-50.7M
↓ 43.12%
Investing Cash Flow
-118.6M
↓ 279.76%
Financing Cash Flow
108.8M
↓ 19.91%
FY22Y/Y Change
Operating Cash Flow
-115.9M
↑ 128.79%
Investing Cash Flow
-13.0M
↓ 89.06%
Financing Cash Flow
83.1M
↓ 23.6%
Q4 FY22Q/Q Change
Operating Cash Flow
-30.4M
↑ 17.8%
Investing Cash Flow
-46.2M
↓ 1600.88%
Financing Cash Flow
64.4M
↑ 232.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-40.1M
↑ 31.99%
Investing Cash Flow
21.2M
↓ 145.88%
Financing Cash Flow
8.6M
↓ 86.57%
Q2 FY23Q/Q Change
Operating Cash Flow
-31.0M
↓ 22.77%
Investing Cash Flow
24.6M
↑ 16.15%
Financing Cash Flow
1.0M
↓ 88.24%

Technicals Summary

Sell

Neutral

Buy

Gritstone Oncology Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gritstone Oncology Inc
Gritstone Oncology Inc
-6.17%
-76.12%
-66.32%
-91.3%
-93.77%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gritstone Oncology Inc
Gritstone Oncology Inc
NA
NA
NA
-1.08
-1.87
-0.52
NA
0.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gritstone Oncology Inc
Gritstone Oncology Inc
Buy
$75.2M
-93.77%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Gritstone Oncology Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 29.0K → 49.0K (in $), with an average increase of 40.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -30.81M → -40.38M (in $), with an average decrease of 31.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 127.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 277.8%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    6.21%

  • BlackRock Inc

    5.33%

  • Redmile Group, LLC

    5.30%

  • Vanguard Group Inc

    4.36%

  • Versant Venture Management LLC

    3.28%

  • Point72 Asset Management, L.P.

    2.83%

Company Information

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Organization
Gritstone Oncology Inc
Employees
231
CEO
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Industry
Health Technology

Discover More

FAQs